title: A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.
abstract: The present investigation aimed at brain targeting of sumatriptan succinate (SS) for its optimal therapeutic effect in migraine through nanoparticulate drug delivery system using poly (butyl cyanoacrylate) (PBCA) and bovine serum albumin linked with apolipoprotein E3 (BSA-ApoE).
  
  
  
  The study involved formulation optimization of PBCA nanoparticles (NPs) using central composite design for achieving minimum particle size, maximum entrapment efficiency along with sustained drug release. SS incorporated in BSA-ApoE NPs (S-AA-NP) were prepared by desolvation technique and compared with SS loaded polysorbate 80 coated optimized PBCA NPs (FPopt) in terms of their brain uptake potential, upon oral administration in male Wistar rats. The NPs were characterized by FTIR, thermal, powder XRD and TEM analysis.
  
  
  
  The in vivo studies of FPopt and S-AA-NP on male Wistar rats demonstrated a fairly high brain/plasma drug ratio of 9.45 and 12.67 respectively 2 h post oral drug administration. The behavioural studies on male Swiss albino mice affirmed the enhanced anti-migraine potential of S-AA-NP than FPopt (P < 0.001).
  
  
  
  The results of this work, therefore, indicate that BSA-ApoE NPs are significantly better than polysorbate 80 coated PBCA NPs for brain targeting of SS (P < 0.05) and also offer an improved therapeutic strategy for migraine management.
authors.affiliation: Department of Pharmaceutical Sciences, G. J. University of Sci. & Tech., Hisar, 125001, India.
authors.forename: Priti
authors.initials: P
authors.lastname: Girotra
authors.affiliation: Department of Pharmaceutical Sciences, G. J. University of Sci. & Tech., Hisar, 125001, India. sksingh_gju@rediffmail.com.
authors.forename: Shailendra Kumar
authors.initials: SK
authors.lastname: Singh
mesh_terms: D000284:Administration, Oral; D000818:Animals; D053318:Apolipoprotein E3 / Q000008:administration & dosage / Q000737:chemistry*; D001921:Brain / Q000187:drug effects*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D065546:Drug Liberation / Q000502:physiology; D004659:Enbucrilate / Q000008:administration & dosage / Q000737:chemistry; D008297:Male; D051379:Mice; D008881:Migraine Disorders / Q000188:drug therapy*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D010316:Particle Size; D011136:Polysorbates / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000008:administration & dosage / Q000737:chemistry*; D018170:Sumatriptan / Q000008:administration & dosage / Q000737:chemistry*
chemical_list: D053318:Apolipoprotein E3; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011136:Polysorbates; D012710:Serum Albumin, Bovine; D018170:Sumatriptan; D004659:Enbucrilate
keywords: BSA; PBCA; apolipoprotein; brain targeting; sumatriptan succinate